Molecular and Cellular Therapies (MCT) is the frontline journal for molecular mechanisms, preclinical and clinical research and development of gene-, peptide-, protein-, and cell-based therapies, including target identification and validation, safety, toxicity, efficacy, efficiency, pharmacokinetics, metabolism, formulation, delivery, pharmacovigilance, biomarkers, new drug application. MCT, central to clinical and translational medicine, will integrate genetics, cell biology, medicine, drug development, therapeutics, and biotechnology to improve the prognosis of patients.

Aims and Scope

Molecular and Cellular Therapies is an online, open access journal which focusses on the basic science and clinical development of molecular and cell-based therapies.

The journal aligns basic research in the development of gene-, peptide-, protein-, and cell-based therapies with clinical and pre-clinical research, to establish new therapy parameters such as treatment pharmacokinetics, delivery, toxicity, efficacy, biomarkers and  novel applications.

In order to establish these parameters, Molecular and Cellular Therapies  welcomes research from a range of disciplines, including, but not limited to, genetics, cell biology, medicine, drug development, therapeutics and biotechnology.

The journal has four sections:

  • HIV pathogenesis and Treatment: Edited by Andrew Badley
  • Nanomedicine: Edited by Dan Peer
  • Regenerative Medicine and Therapies: Edited by Marek Malecki
  • Noncoding RNA Therapies: Edited by Ulf Andersson Ørom

Molecular and Cellular Therapies accepts research articles, reviews, commentaries, methodologies and short reports.